Trade

with

Neuralstem Inc
(Amex: CUR)
AdChoices
2.77
-0.04
-1.42%
After Hours :
2.77
0.00
0.00%

Open

2.81

Previous Close

2.81

Volume (Avg)

336.46k (617.61k)

Day's Range

2.76-2.82

52Wk Range

2.12-4.81

Market Cap.

244.01M

Dividend Rate ( Yield )

-

Beta

1.71

Shares Outstanding

86.84M

P/E Ratio (EPS)

-

AdChoices
Fundamentals
  • Key statistics
  • Growth
  • Profitability
  • Financial health
  • Price ratios
  • Trading statistics
  • Management effectiveness
Industry Biotechnology
Highlights
Analyst Recommendation: Hold
    • Revenue

    • 110.00k

    • Net Income

    • -19.83M

    • Market Cap.

    • 244.01M

    • Enterprise Value

    • -

    • Net Profit Margin %

    • -159,952.59

    • PEG (Price/Earnings Growth) Ratio

    • -

    • Beta

    • 1.71

    • Forward P/E

    • -11.71

    • Price/Sales

    • 10,000.00

    • Price/Book Value

    • 10.15

    • Price/Cash flow

    • -21.83

      • EBITDA

      • -18.19M

      • Return on Capital %

      • -97.62

      • Return on Equity %

      • -159.35

      • Return on Assets %

      • -97.62

      • Book Value/Share

      • 0.28

      • Shares Outstanding

      • 86.84M

      • Last Split Factor (Date)

      • -

      • Last Dividend (Ex-Date)

      • -

      • Dividend Declaration Date

      • -

      Analyst Recommendation
      10/21/2014
      Hold
        • 1 Year Price Target

        • 7.00

        • Credit Rating

        • -

        • Analysts

        • 3

        • EPS Estimate

        • -0.24

        • Cashflow Estimate

        • -

        Morningstar Consensus estimate data
        • Growth Rate (%)

        • Company

        • Industry

          • Sales (Revenue)

            Q/Q (last year)

          • 100.00

          • 40.73

          • Net Income

            YTD/YTD (last year)

          • -

          • 17.04

          • Net Income

            Q/Q (last year)

          • -

          • 98.90

          • Sales (Revenue)

            5-Year Annual Average

          • -

          • 63.43

          • Net Income

            5-Year Annual Average

          • -

          • 10.65

          • Dividends

            5-Year Annual Average

          • -

          • 15.81

          • Profit Margins (%)

          • Company

          • Industry

            • Gross Margin

            • 100.00

            • 82.75

            • Pre-Tax Margin

            • -159,952.59

            • 39.38

            • Net Profit Margin

            • -159,952.59

            • 31.33

            • Average Gross Margin

              5-Year Annual Average

            • -

            • 82.99

            • Average Pre-Tax Margin

              5-Year Annual Average

            • -

            • 33.42

            • Average Net Profit Margin

              5-Year Annual Average

            • -

            • 199.05B

            • Financial Ratios

            • Company

            • Industry

              • Debt/Equity Ratio

              • 0.14

              • 0.76

              • Current Ratio

              • 6.18

              • 2.92

              • Quick Ratio

              • 6.06

              • 2.35

              • Interest Coverage

              • -12.04

              • 38.02

              • Leverage Ratio

              • 1.36

              • 2.21

              • Book Value/Share

              • 0.28

              • 4.79

              • Price Ratios

              • Company

              • Industry

                • Current P/E Ratio

                • -9.48

                • 243.90

                • P/E Ratio 5-Year High

                • -17.13

                • 634.30

                • P/E Ratio 5-Year Low

                • -1.50

                • 124.82

                • Price/Sales Ratio

                • 10,000.00

                • 9.29

                • Price/Book Value

                • 9.62

                • 8.39

                • Price/Cash Flow Ratio

                • -21.83

                • 49.75

                • Key Metrics

                • Company

                  • Shares Short

                    as of -

                  • -

                  • Short Ratio

                    as of -

                  • -

                  • Short % of Float

                    as of -

                  • -

                  • Shares Short

                    prior month

                  • -

                  • Trailing Annual Dividend Yield

                  • -

                  • 5 Year Average Dividend Yield

                  • -

                  • Key Metrics

                  • Company

                    • Payout Ratio

                    • -

                    • Dividend Date

                    • -

                    • Ex-Dividend Date

                    • -

                    • Last Split Factor

                      new per old

                    • -

                    • Last Split Date

                    • -

                    • Key Metrics

                    • Company

                    • Industry

                      • Return on Equity %

                        (5-Year Average)

                      • -159.35

                        (-)

                      • 37.63

                        (27.20)

                      • Return on Assets %

                        (5-Year Average)

                      • -97.62

                        (-196.80)

                      • 17.22

                        (13.81)

                      • Return on Capital %

                        (5-Year Average)

                      • -98.67

                        (-)

                      • 21.78

                        (17.31)

                      • Income/Employee

                      • -

                      • 117.08k

                      • Inventory Turnover

                      • -

                      • 1.48

                      • Asset Turnover

                      • 0.00

                      • 0.55

                      Current Historical
                      Financials
                      • Income Statement
                      • Balance Sheet
                      • Cash Flow
                      Operating Income
                      -12.52M
                      Operating Margin
                      -11,385.40
                      Total Equity
                      -
                      Retained Earnings
                      -
                      Free Cashflow
                      -
                      Price/Cashflow
                      -21.83
                      Ownership

                      Institutional Ownership

                      18.38%

                      Top 10 Institutions

                      13.45%

                      Mutual Fund Ownership

                      12.87%

                      Float

                      95.70%

                      5% / Insider Ownership

                      2.22%

                      Corporate insiders or major stockholders reporting trading activity in the stock.

                      Top Mutual Fund Owners

                      Top Institutional Owners

                      Mutual Fund Name

                      Institution Name

                      • Mutual Fund Name

                      • Shares Held

                      • % Change

                      • % Outstanding

                      • Putnam Multi-Cap Growth

                      •  

                        2,031,211

                      • 17.14

                      • 2.34

                      • Vanguard Total Stock Mkt Idx

                      •  

                        1,298,798

                      • 0.00

                      • 1.50

                      • Vanguard Extended Market Index Fund

                      •  

                        1,075,363

                      • 0.00

                      • 1.24

                      • iShares Russell 2000 (AU)

                      •  

                        1,028,111

                      • -1.81

                      • 0.96

                      • Alger Health Sciences Portfolio

                      •  

                        517,250

                      • 0.00

                      • 0.60

                      • Alger Small Cap Growth Institutional Fd

                      •  

                        495,800

                      • 0.00

                      • 0.57

                      • Putnam Global Health Care Fund

                      •  

                        491,038

                      • 0.00

                      • 0.57

                      • iShares Russell 2000 Growth

                      •  

                        490,227

                      • -1.57

                      • 0.46

                      • Putnam VT Multi-Cap Growth Fund

                      •  

                        402,839

                      • 15.41

                      • 0.46

                      • IG Putnam US Growth Fund

                      •  

                        308,535

                      • 32.46

                      • 0.36

                      • Institution Name

                      • Shares Held

                      • % Change

                      • % Outstanding

                      • Putnam Investment Management,LLC

                      •  

                        3,522,415

                      • +17.66%

                      • 4.06

                      • Vanguard Group, Inc.

                      •  

                        2,621,233

                      • +12.58%

                      • 3.02

                      • BlackRock Fund Advisors

                      •  

                        1,707,150

                      • +798.76%

                      • 1.97

                      • Fred Alger Management, Inc.

                      •  

                        1,428,410

                      • -19.99%

                      • 1.64

                      • State Street Corp

                      •  

                        652,092

                      • +1,550.87%

                      • 0.75

                      • Credit Suisse First Boston (CSFB)

                      •  

                        439,095

                      • -28.80%

                      • 0.51

                      • Geode Capital Management, LLC

                      •  

                        434,041

                      • +12.70%

                      • 0.50

                      • I.G. Investment Management, Ltd

                      •  

                        308,535

                      • +32.46%

                      • 0.36

                      • Millennium Management LLC

                      •  

                        280,399

                      • +1,353.52%

                      • 0.32

                      Company Profile

                      Sector

                      Healthcare

                      Industry

                      Biotechnology

                      Type

                      Distressed

                      Style

                      Small Growth

                      Neuralstem, Inc. was incorporated in 1996 in the state of Maryland. In 2001 it re-incorporated in the state of Delaware. It is engaged in development and commercialization of treatments for central nervous system disease based on tra...morensplanting human neural stem cells and the use of small molecule drugs. The Company has developed and maintains a portfolio of patents and patent applications that form the proprietary base of its research and development efforts in the area of neural stem cell research, and related technologies. Its technology base, in combination with its know-how, and collaborative projects with research institutions, provide a competitive advantage and would facilitate the successful development and commercialization of products for use in treatment of an array of neurodegenerative c...moreonditions and in regenerative repair of acute disease. The Company is focused on leveraging its key assets, including its intellectual property, its scientific team, its facilities and its capital, to accelerate the advancement of its stem cell technologies. In addition, it is pursuing strategic collaborations with members of academia. The Company manufactures its cells both in-house and on an outsource basis. It uses these cells in its research and collaborative programs. It outsources all the manufacturing and storage of its stem cells to be used in pre-clinical works, and which are accordingly subject to higher FDA requirements, to Charles River Laboratories, Inc., of Wilmington, Massachusetts. The Company’s competitors include multinational pharmaceutical companies, specialty biotechnology companies and chemical and medical products companies operating in the fields of regenerative medicine, cell therapy, tissue engineering and tissue regeneration. Many of these companies are well-established and possess technical, research and development, financial and sales and marketing resources greater than the Company. The Company is subject to various U.S. federal, state, local and international laws, regulations and recommendations relating to safe working conditions, laboratory and manufacturing practices and the use and disposal of hazardous or potentially hazardous substances, including radioactive compounds and infectious disease agents, used in connection with its business.lessless

                      Key People

                      I. Richard Garr

                      CEO/CFO/Chief Accounting Officer/Director/General Counsel/President

                      Dr. Karl Johe,PhD

                      Chairman of the Board/Chief Scientific Officer/Director

                      Sandford D. Smith

                      Director

                      Dr. Catherine A. Sohn

                      Director

                      Stanley I. Westreich

                      Director

                      • Neuralstem Inc

                      • 9700 Great Seneca Highway

                      • Rockville, MD 20850

                      • USA.Map

                      • Phone: +1 301 366-4841

                      • Fax: -

                      • neuralstem.com

                      Incorporated

                      1997

                      Employees

                      15

                      Send Feedback

                      We appreciate your input!

                      • I'm having trouble signing into my Microsoft account

                      • I’m having problems with the services stripe (Mail, Facebook, etc.)

                      • There is an issue with my weather information

                      • I see an error in the content

                      • Other

                      Please give an overall site rating: